Holen Sie sich die Stockscreener-App
17.77
5.02%
0.85
Schlusskurs vom Vortag:
$16.92
Offen:
$17.24
24-Stunden-Volumen:
433.12K
Relative Volume:
1.03
Marktkapitalisierung:
$481.34M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-15.32
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
-1.55%
1M Leistung:
+8.29%
6M Leistung:
-18.78%
1J Leistung:
-49.63%
1-Tages-Spanne:
$16.63
$17.86
1-Wochen-Bereich:
$16.54
$19.25
52-Wochen-Spanne:
$14.30
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
17.77 | 481.34M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January - MarketBeat
Empire Life Investments Inc. Purchases 128,771 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
The week in pharma: action, reaction and insight – week to February 14 - The Pharma Letter
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts - Defense World
Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $65.00 - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
EC approves CSL and Arcturus’ Kostaive - The Pharma Letter
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine - Marketscreener.com
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views - Benzinga
ARCTArcturus Therape Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive - Marketscreener.com
EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics - Nasdaq
Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval - StockTitan
Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - StockTitan
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - The Malaysian Reserve
Selling Arcturus Therapeutics Holdings Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
SG Americas Securities LLC Has $203,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN
State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com
Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com Australia
Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6% - MarketBeat
Global mRNA Vaccines and Therapeutics Market is expected - openPR
Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat
Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace
BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq
Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga
BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com
Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia. - ACCESS Newswire
Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World
What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat
Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World
Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):